Genprex (GNPX) Receivables - Net (2016 - 2022)

Genprex (GNPX) posted quarterly Receivables - Net of $34852.0 for Q4 2022, little changed quarter-over-quarter from $34852.0 in Q3 2022.

Genprex (GNPX) Receivables - Net (2016 - 2022) Analysis & Trends

Genprex's Receivables - Net history runs 7 years deep, the most recent figure standing at $34852.0 for Q4 2022.

In Q4 2022, Receivables - Net changed N/A year-over-year to $34852.0; the TTM figure through Dec 2022 stood at $34852.0 (changed N/A YoY), while the FY2022 annual figure was $34852.0, changed N/A from the prior year.
Receivables - Net for Q4 2022 stood at $34852.0, roughly flat from $34852.0 in the prior quarter.
The five-year high for Receivables - Net was $34852.0 in Q3 2022, with the low at $85.0 in Q2 2020.
The 5-year median for Receivables - Net is $746.5 (2018), against an average of $9517.2.
The sharpest annual moves came in 2020 and 2022: Receivables - Net sank 99.21% in 2020, then jumped 27342.52% in 2022.
Genprex's Receivables - Net stood at $9297.0 in 2018, then sank by 92.95% to $655.0 in 2019, then sank by 80.61% to $127.0 in 2020, then changed by 0.0% to $127.0 in 2021, then surged by 27342.52% to $34852.0 in 2022.
Business Quant data shows GNPX's Receivables - Net at $34852.0 in Q4 2022, $34852.0 in Q3 2022, and $32171.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.81 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.52 Bn	3.93 Bn
3	Argenx Se	65.30 Bn	60.11 Bn	1.37 Bn
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.77 Bn	28.46 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.74 Bn	668.28 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn
9	Royalty Pharma	27.16 Bn	26.32 Bn	-
10	Genprex	2.03 Mn	-13.12 Mn	-

Download Data